Medplus Health Services Ltd
₹ 809
2.59%
28 Nov
- close price
About
Key Points
- Market Cap ₹ 9,691 Cr.
- Current Price ₹ 809
- High / Low ₹ 1,052 / 603
- Stock P/E 185
- Book Value ₹ 106
- Dividend Yield 0.00 %
- ROCE 4.58 %
- ROE 3.32 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 29.4% CAGR over last 5 years
- Company's median sales growth is 46.8% of last 10 years
Cons
- Stock is trading at 7.59 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 1.57% over last 3 years.
- Promoters have pledged or encumbered 59.3% of their holding.
- Working capital days have increased from 53.4 days to 76.5 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 2 | 2 | 9 | 10 | 61 | 68 | 146 | 214 | 467 | 713 | 768 | |
| 6 | 7 | 4 | 14 | 13 | 86 | 77 | 142 | 208 | 435 | 635 | 675 | |
| Operating Profit | -3 | -5 | -2 | -5 | -3 | -25 | -9 | 3 | 6 | 32 | 78 | 94 |
| OPM % | -137% | -225% | -89% | -52% | -36% | -41% | -13% | 2% | 3% | 7% | 11% | 12% |
| -1 | 1 | 0 | 1 | 1 | 2 | 2 | 10 | 23 | 7 | 9 | 10 | |
| Interest | 1 | 0 | 0 | 12 | 0 | 0 | 1 | 3 | 7 | 8 | 9 | 9 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 15 | 24 | 27 | 27 |
| Profit before tax | -5 | -4 | -2 | -16 | -3 | -24 | -9 | 6 | 8 | 7 | 51 | 68 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 2% | 0% | 0% | 27% | -36% | 21% | |
| -5 | -4 | -2 | -16 | -3 | -25 | -9 | 6 | 6 | 9 | 40 | 53 | |
| EPS in Rs | -292.30 | -241.71 | -109.61 | -793.71 | -126.23 | -1,220.91 | -186.95 | 0.47 | 0.46 | 0.79 | 3.37 | 4.38 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 77% |
| 5 Years: | 63% |
| 3 Years: | 70% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 29% |
| 3 Years: | 95% |
| TTM: | 75% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| 1 Year: | 3% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 1% |
| 3 Years: | 2% |
| Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.17 | 0.17 | 0.17 | 0.19 | 0.19 | 0.19 | 0.45 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 126 | 108 | 88 | 185 | 185 | 395 | 517 | 1,089 | 1,117 | 1,164 | 1,216 | 1,252 |
| 55 | 55 | 55 | 0 | 0 | 3 | 7 | 44 | 86 | 89 | 95 | 101 | |
| 6 | 21 | 39 | 3 | 6 | 17 | 24 | 30 | 45 | 33 | 65 | 52 | |
| Total Liabilities | 187 | 185 | 183 | 189 | 192 | 415 | 548 | 1,187 | 1,272 | 1,310 | 1,399 | 1,430 |
| 1 | 1 | 0 | 0 | 0 | 7 | 23 | 85 | 179 | 192 | 184 | 184 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 16 | 18 | 0 | 1 | 1 |
| Investments | 153 | 177 | 177 | 181 | 186 | 381 | 408 | 418 | 917 | 923 | 928 | 930 |
| 34 | 6 | 5 | 8 | 5 | 26 | 115 | 668 | 157 | 196 | 286 | 314 | |
| Total Assets | 187 | 185 | 183 | 189 | 192 | 415 | 548 | 1,187 | 1,272 | 1,310 | 1,399 | 1,430 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -5 | -4 | -2 | -1 | -1 | -0 | -6 | -18 | 11 | 8 | 47 | |
| -11 | -24 | 0 | -2 | -3 | -194 | -15 | -636 | 32 | -24 | -39 | |
| 46 | 0 | 0 | 7 | 0 | 204 | 97 | 569 | -8 | -6 | -10 | |
| Net Cash Flow | 30 | -28 | -1 | 4 | -4 | 10 | 76 | -86 | 35 | -22 | -2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 29 | 14 | 22 | 80 | 51 | 62 | 53 | 64 | 54 | 62 |
| Inventory Days | 33 | 35 | 12 | 16 | 15 | 12 | |||||
| Days Payable | 9 | 17 | 17 | 30 | 19 | 30 | |||||
| Cash Conversion Cycle | 32 | 29 | 14 | 22 | 80 | 75 | 79 | 48 | 50 | 50 | 44 |
| Working Capital Days | -78 | -72 | -130 | -97 | -145 | -12 | -20 | 1,547 | 21 | 62 | 76 |
| ROCE % | -2% | -1% | -2% | -1% | -8% | -2% | 1% | 1% | 1% | 5% |
Documents
Announcements
-
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
3h - Two-day drug licence suspension at Medipally Uppal store; order received 29 Nov 2025; loss ~Rs1.43 lakh
-
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
1d - Two two-day drug-license suspensions; Telangana and Andhra stores; potential revenue loss ~Rs1.73 lakh.
-
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
27 Nov - Two-day drug-license suspension (order received 26 Nov 2025) for MedPlus subsidiary store; estimated revenue loss Rs 1.31 lakh.
-
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
25 Nov - Optival subsidiary received two-day drug-license suspension in Nizamabad on 24-Nov-2025; potential revenue loss ~Rs0.72 lakh.
-
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015.
22 Nov - Subsidiary store in Alnavara, Karnataka received one-day drug-license suspension on 21-Nov-2025; estimated loss ~Rs0.33 Lacs.
Annual reports
Concalls
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
India's Leading Pharmacy Company[1][2]
MedPlus is the 2nd largest pharmacy retailer in India, with 4,552 stores across 12 states and 1 union territory as of Q2 FY25. These stores are strategically distributed to maintain a high presence in metro, tier-one, and tier-two cities.
The stores increased with 108 net new stores added in Q2 FY2025, of which 71 were in Tier-2 and Tier-3 cities[3]